The BioPump™ Process

      1. Harvest “micro-organ” from the dermis using the proprietary DermaVac device
      2. Transduce micro-organ ex-vivo with viral vector to create a mini “protein factory” or BioPump
      3. Implant the BioPump into patient where it produces a therapeutic protein (biologic drug)

 

Key Advantages of BioPump:

Continuous, autologous protein production that offers several advantages over recombinant protein therapies:

 

Improved safety, tolerability,
and compliance:

 

Capital efficient, de-risked
path to drug development:

  • Patients become their own “bioreactor” producing protein with unique autologous glycosylation patterns
  • Longer duration in vivo
  • Greater cell uptake
  • Less immunogenicity
 
  • Ex-vivo transduction eliminates patient exposure to viral vectors typically seen in gene therapy
  • Reduced chance of developing neutralizing antibodies which can lead to reduced efficacy and anaphylactic reactions
  • Ability to control dosing through the addition and removal of BioPumps
  • Implantation ensures compliance, better outcomes, and provides control of the product
 
  • Exogenous gene therapy on “tummy tuck” tissue is performed to test human protein expression in vitro
  • Severe combined immunodeficient (SCID) mice provide predictive in vivo model for protein expression and duration
  • In vitro (human) and in vivo (SCID mouse) models provide
    pre-clinical POC, for approximately $100K and less than 6 months
  • Using patients as their own bioreactor eliminates need for large investment in manufacturing and scale up for clinical trial material